1. Outcome of the radical hypofractioned radiotherapy treatment in patients with stage I and II of non-small cell lung cancer
- Author
-
Maria Wilczynska and Angel Garcia-Alonso
- Subjects
Oncology ,Hypofractionated Radiotherapy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,medicine.disease ,Surgery ,Radiation therapy ,Internal medicine ,Total dose ,medicine ,Radiology, Nuclear Medicine and imaging ,In patient ,Radiotherapy treatment ,Non small cell ,Stage (cooking) ,Lung cancer ,business - Abstract
Introduction: Surgery is the treatment of choice in stage I and II non-small-cell lung cancer (NSCLC). In the management of patients who are medically unfit to tolerate surgical intervention or who refuse surgery, radiotherapy is an acceptable alternative. We have performed a retrospective analysis of the effectiveness of radical radiotherapy in patients with early stage NSCLC treated over a period of 4 years.Methods: Thirty nine patients treated with radiotherapy of radical intent were identified. All patients received hypofractionated radiotherapy with a total dose of 55Gy in 20 fractions.Results: The median survival of all cases was 29 months. The one and two-year survival was respectively 61 % and 41%. The median survival of patients ≥75 years was 28 months, and age was the only prognostic factor identified in this analysis that affected survival.Conclusions: The presented survival results are consistent with those from other series published in the literature. At present, radical radiotherapy is often offered to patients with medically inoperable stage I and II NSCLC or those who decline surgery. But there is emerging evidence that some new techniques like stereotactic radiotherapy could be also used in the operable, early stage NSCLC.
- Published
- 2012
- Full Text
- View/download PDF